GlassScriptPhysician profile
Lawrence D Stutte
NPI 1093819252
$783.57
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $108 · 2021: $119 · 2022: $101.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $139.24 | 2019-2022 | |
| Novo Nordisk INC | $112.50 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $84.42 | 2019 | |
| Astellas Pharma US INC | $66.52 | 2019 | |
| Merck Sharp & Dohme LLC | $45.24 | 2019-2020 | |
| Amgen INC. | $43.09 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $37.76 | 2019-2021 | |
| Eisai INC. | $37.45 | 2020 | |
| Janssen Pharmaceuticals, INC | $35.26 | 2019 | |
| Amarin Pharma, INC. | $33.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.32 | 2019 | |
| Abbvie INC. | $19.41 | 2021 | |
| Janssen Biotech, INC. | $19.03 | 2022 | |
| Glaxosmithkline, LLC. | $17.09 | 2021 | |
| Allergan, INC. | $16.90 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $14.41 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.20 | 2019 | |
| Lilly USA, LLC | $12.37 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.28 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Stutte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.